Story
Arm Stock Gains as CEO Signals Progress on Meeting AGI Chip Demand

Summary
Shares of the chip designer climbed after CEO Rene Haas expressed growing confidence in the company's ability to convert over $2 billion in customer demand for its new AGI data center processor into revenue.
Arm Holdings (NASDAQ: ARM) ADRs rose 3.3% in pre-open trading after CEO Rene Haas signaled that the company is making material progress in securing manufacturing capacity for its highly anticipated AGI data center processor, addressing a key investor concern.
CEO Addresses Supply Bottleneck
Speaking on CNBC's "Mad Money," Haas stated he has growing confidence that Arm can convert $2 billion in customer demand for its AGI CPU into actual revenue. This directly addresses the discrepancy between strong customer interest and the company's more conservative $1 billion official revenue target, which was set due to previous uncertainties around securing manufacturing supply.
The AGI CPU marks a significant strategic shift for Arm, moving from its traditional model of licensing chip designs to selling a complete, self-designed processor for data centers. According to the report, customer demand visibility for the chip had doubled from $1 billion in March to over $2 billion by May. Haas's latest comments, noting that supply arrangements have "improved materially" since the July earnings call, suggest the gap between demand and deliverable supply is narrowing.
AdBroader Market Lends Support
The move in Arm's stock was amplified by a constructive market environment. Major U.S. indices were trading higher in the pre-market session after investors digested a widely expected 25-basis-point interest rate increase from the Federal Reserve without significant disruption.
Sentiment in the semiconductor sector was also positive, with peers like Nvidia (NASDAQ: NVDA) and Broadcom (NASDAQ: AVGO) participating in a broader rally driven by the ongoing narrative of robust spending on AI infrastructure. This combination of company-specific positive news and a supportive macro backdrop helped push Arm shares higher, though the stock remains well below its 52-week high of $452.70.
Read next
More on Stocks
Novo Nordisk, Orbis Medicines Ink $1.4 Billion Deal for Oral Cardiometabolic Drugs
Orbis Medicines and Novo Nordisk have entered a licensing collaboration potentially worth up to $1.4 billion to develop oral versions of injectable drugs for cardiometabolic diseases, leveraging Orbis's AI-driven discovery platform.

Robinhood Shares Rise After SEC Issues Guidance on Tokenized Securities
Shares of Robinhood Markets (HOOD) climbed after the U.S. Securities and Exchange Commission introduced a five-year plan allowing for the trading of tokenized stocks on designated venues.

Gold Prices Face Near-Term Pressure From Strong US Data, Higher Yields
Gold is trading in a narrow range as robust economic indicators bolster Treasury yields, creating headwinds for the non-yielding asset. The medium-term outlook remains constructive, contingent on a potential shift in monetary policy and persistent structural demand.

UBS Upgrades Industrial Metals to Overweight, Citing Long-Term Structural Tailwinds
UBS has raised its outlook on industrial metals to Overweight, arguing that structural forces like the energy transition and chronic underinvestment will support prices in the coming years.